查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1452672

全球顱內治療遞送市場 - 全球產業分析、規模、佔有率、成長、趨勢、預測 (2031) - 依治療、依適應症、依地區

Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 168 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球顱內治療服務市場正處於前所未有的成長邊緣。 預計到 2024 年，該市場價值將達到 22 億美元，並預計在未來十年以 9% 的複合年增長率快速增長，到 2031 年將達到驚人的 40 億美元。 這一激增反映了對神經病學創新治療的需求不斷增長以及全球神經系統疾病盛行率的上升。

顱內治療遞送在 2021 年約佔全球再生醫學市場的 6.1%，處於病患照護變革的最前線。 這個領域非常重視細胞、基因和酵素替代療法，為無數疾病的治療帶來了新的曙光，並為傳統療法的不足帶來了希望。

從 2018 年到 2023 年，顱內治療遞送方法的受歡迎程度和有效性顯著上升，特別是在細胞和基因治療領域。 這種範式轉移得到了包括Bristol Myers Squibb、Gilead Sciences &Company、Xcell Biosciences Inc.在內的生物製藥巨頭的廣泛研究和合作的支持，並強調疾病管理和預防的變革性方法。 透過策略收購和合作，這些領先公司對卓越的追求正在創造新的行業基準。

本報告研究了全球顱內治療遞送市場，並提供了市場概述，包括依治療、適應症、區域劃分的趨勢以及進入市場的公司的競爭趨勢。

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第 3 章2018-2031 年全球顱內治療實施市場展望

  • 2018-2031 年全球顱內治療遞送市場前景（依治療方式、價值（十億美元））
  • 2018-2031 年全球顱內治療遞送市場展望（依適應症、價值（十億美元））
  • 2018-2031 年全球顱內治療遞送市場前景（依地區、價值（十億美元））

第 4 章北美顱內治療實施市場展望，2018-2031

第五章歐洲顱內治療實施市場展望，2018-2031

第 6 章亞太地區顱內治療遞送市場展望，2018-2031 年

第 7 章拉丁美洲顱內治療遞送市場展望，2018-2031 年

第 8 章中東和非洲顱內治療遞送市場前景，2018-2031

第九章競爭態勢

  • 依治療方法和適應症劃分的熱圖
  • 2023 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Novartis AG
    • BioMarin
    • CORESTEM Inc.
    • Alaunos Therapeutics, Inc.
    • Apic Bio
    • Stemedica Cell Technologies, Inc.
    • Voyager Therapeutics
    • Bayer AG
    • Abeona Therapeutics
    • Spark Therapeutics

第 10 章附錄

簡介目錄

The global intracranial therapeutic delivery market is poised for unprecedented growth. According to a comprehensive market analysis, the sector, valued at US$ 2.2 billion in 2024, is projected to burgeon at a compound annual growth rate (CAGR) of 9% over the next decade, culminating in a staggering US$ 4 billion by 2031. This surge reflects the increasing demand for innovative treatments in neurology and the rising prevalence of neurological disorders worldwide.

Intracranial Therapeutic Delivery: A Pillar of Regenerative Medicine

Accounting for approximately 6.1% of the global regenerative medicine market in 2021, intracranial therapeutic delivery stands at the forefront of transforming patient care. With a significant emphasis on cell, gene, and enzyme replacement therapies, this sector promises a new dawn in the treatment of a myriad of conditions, offering hope where traditional modalities fall short.

A Decade in Review: Triumphs and Innovations

The period from 2018 to 2023 has witnessed a notable ascent in the popularity and efficacy of intracranial therapeutic delivery methods, especially in the realms of cell and gene therapy. This paradigm shift, underpinned by extensive research and collaboration among biopharmaceutical giants such as Bristol Myers Squibb, Gilead Sciences & Company, and Xcell Biosciences Inc., underscores a transformative approach to disease management and prevention. The pursuit of excellence by these key players, through strategic acquisitions and partnerships, is setting new benchmarks in the industry.

Market Drivers: A Confluence of Innovation and Opportunity

The market's trajectory is notably influenced by the burgeoning pipeline of cell, gene, and enzyme replacement therapies, which account for a substantial portion of the pharmaceutical industry's research focus. With over 750 trials and more than 200 investigational new drug applications anticipated by the U.S. FDA, the sector is on the cusp of delivering groundbreaking treatments to patients across the globe.

Moreover, a tangible shift towards regenerative therapies over conventional drug-based treatments is reshaping the landscape. These advancements, coupled with supportive government policies, especially in emerging economies, herald a new era of healthcare possibilities.

Challenges and Constraints: Navigating Through Uncertainties

Despite the optimistic outlook, the market faces hurdles, primarily due to the high costs associated with these advanced therapies. The financial implications for patients and healthcare systems, along with a lack of comprehensive reimbursement policies, present significant challenges. Addressing these concerns is crucial for ensuring the accessibility and sustainability of intracranial therapeutic delivery methods.

Geographical Insights: Key Markets and Emerging Players

  • United States: Leading the charge with a 36.4% market share, the U.S. is a hotbed for R&D, bolstered by robust government support and regulatory frameworks.
  • Germany: With a quarter share of the European market, Germany's robust healthcare expenditure and thriving biopharmaceutical landscape make it a key player in the sector.
  • United Kingdom: The U.K.'s commitment to regenerative medicine and its significant contribution to the European advanced therapeutic medicinal products (ATMP) sector underscore its pivotal role in the market's growth.
  • South Korea: Demonstrating rapid progress, South Korea's strategic investments in biopharma and biotech are unlocking new possibilities in intracranial therapeutic delivery.

The Competitive Landscape: Fostering Innovation and Collaboration

The market's future is shaped by strategic collaborations, mergers, and acquisitions among leading firms. Innovations and product launches are critical for maintaining competitive advantage and addressing the evolving needs of patients worldwide. Notable developments, such as ElevateBio's lentiviral vector production platform and the collaboration between Biogen and Ginkgo Bioworks, highlight the industry's commitment to revolutionizing intracranial therapeutic delivery.

Key Companies Profiled

  • Novartis AG
  • BioMarin
  • CORESTEM Inc.
  • Alaunos Therapeutics, Inc.
  • Apic Bio
  • Stemedica Cell Technologies, Inc.
  • Voyager Therapeutics
  • Bayer AG
  • Abeona Therapeutics
  • Spark Therapeutics

Segmentation of Intracranial Therapeutic Delivery Industry

Intracranial Therapeutic Delivery Market by Therapy:

  • Cell-based Therapy
  • Gene Therapy
  • Enzyme Replacement Therapy

Intracranial Therapeutic Delivery Market by Indication:

  • Spinal Muscular Atrophy (SMA)
  • Multiple Sclerosis
  • Batten Disease
  • Amyotrophic Lateral Sclerosis

Intracranial Therapeutic Delivery Market by Region:

  • U.S. Intracranial Therapeutic Delivery Market
  • Europe Intracranial Therapeutic Delivery Market
  • Rest of the World (ROW) Intracranial Therapeutic Delivery Market

Table of Contents

1. Executive Summary

  • 1.1. Global Intracranial Therapeutic Delivery Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 3.1. Global Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cell-based Therapy
      • 3.1.1.2. Gene Therapy
      • 3.1.1.3. Enzyme Replacement Therapy
  • 3.2. Global Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Spinal Muscular Atrophy (SMA)
      • 3.2.1.2. Multiple Sclerosis
      • 3.2.1.3. Batten Disease
      • 3.2.1.4. Amyotrophic Lateral Sclerosis
  • 3.3. Global Intracranial Therapeutic Delivery Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 4.1. North America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Cell-based Therapy
      • 4.1.1.2. Gene Therapy
      • 4.1.1.3. Enzyme Replacement Therapy
  • 4.2. North America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Spinal Muscular Atrophy (SMA)
      • 4.2.1.2. Multiple Sclerosis
      • 4.2.1.3. Batten Disease
      • 4.2.1.4. Amyotrophic Lateral Sclerosis
  • 4.3. North America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 5.1. Europe Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cell-based Therapy
      • 5.1.1.2. Gene Therapy
      • 5.1.1.3. Enzyme Replacement Therapy
  • 5.2. Europe Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Spinal Muscular Atrophy (SMA)
      • 5.2.1.2. Multiple Sclerosis
      • 5.2.1.3. Batten Disease
      • 5.2.1.4. Amyotrophic Lateral Sclerosis
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
      • 5.3.1.8. Italy Intracranial Therapeutic Delivery Market by Indication, Value (US$Bn), 2018 - 2031
      • 5.3.1.9. Turkey Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cell-based Therapy
      • 6.1.1.2. Gene Therapy
      • 6.1.1.3. Enzyme Replacement Therapy
  • 6.2. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Spinal Muscular Atrophy (SMA)
      • 6.2.1.2. Multiple Sclerosis
      • 6.2.1.3. Batten Disease
      • 6.2.1.4. Amyotrophic Lateral Sclerosis
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
      • 6.3.1.2. China Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 7.1. Latin America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cell-based Therapy
      • 7.1.1.2. Gene Therapy
      • 7.1.1.3. Enzyme Replacement Therapy
  • 7.2. Latin America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Spinal Muscular Atrophy (SMA)
      • 7.2.1.2. Multiple Sclerosis
      • 7.2.1.3. Batten Disease
      • 7.2.1.4. Amyotrophic Lateral Sclerosis
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cell-based Therapy
      • 8.1.1.2. Gene Therapy
      • 8.1.1.3. Enzyme Replacement Therapy
  • 8.2. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Spinal Muscular Atrophy (SMA)
      • 8.2.1.2. Multiple Sclerosis
      • 8.2.1.3. Batten Disease
      • 8.2.1.4. Amyotrophic Lateral Sclerosis
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Therapy vs by Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. BioMarin
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. CORESTEM Inc.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Alaunos Therapeutics, Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Apic Bio
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Stemedica Cell Technologies, Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Voyager Therapeutics
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Bayer AG
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Abeona Therapeutics
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Spark Therapeutics
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations

List of Region/Countries

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Turkey
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa